Credit Suisse Double Downgrades Edge Therapeutics (EDGE) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts EDGE Hot Sheet
Price: $51.71 -0.5%
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Credit Suisse downgraded Edge Therapeutics (NASDAQ: EDGE) from Outperform to Underperform with a price target of $1.00 (from $17.00).
For an analyst ratings summary and ratings history on Edge Therapeutics click here. For more ratings news on Edge Therapeutics click here.
Shares of Edge Therapeutics closed at $1.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
- Indusind Bank Ltd (IIB:IN) PT Raised to INR900 at UBS
- JPMorgan Upgrades Indusind Bank Ltd (IIB:IN) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
